Top Page
Althea Group Holdings Ltd.
(Sydney:AGH)
Althea Group Holdings Ltd. (AGH) vs. iShares MSCI Australia ETF (EWA)
Althea Group Holdings Ltd. Business Overview & Revenue Model
Althea Group Holdings Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 24.93M | 29.40M | 24.82M | 20.08M | 11.07M | 4.97M | Gross Profit |
| 7.36M | 17.46M | -3.28M | -5.41M | -9.84M | -4.25M | EBIT |
| -7.13M | -11.70M | -12.46M | -12.77M | -15.40M | -12.01M | EBITDA |
| -15.69M | -28.56M | -10.23M | -9.07M | -12.85M | -13.22M | Net Income Common Stockholders |
| -16.95M | -32.06M | -13.72M | -12.12M | -15.05M | -14.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 563.00K | 331.00K | 3.87M | 6.21M | 6.39M | 10.14M | Total Assets |
| 24.33M | 23.65M | 48.34M | 56.56M | 53.91M | 52.38M | Total Debt |
| 6.96M | 6.54M | 4.85M | 5.14M | 4.05M | 2.72M | Net Debt |
| 6.40M | 6.21M | 978.00K | -1.07M | -2.34M | -7.42M | Total Liabilities |
| 23.98M | 23.34M | 18.57M | 15.12M | 11.22M | 6.26M | Stockholders Equity |
| 349.00K | 314.00K | 29.77M | 41.45M | 42.70M | 46.12M |
| Cash Flow | Free Cash Flow | ||||
| -6.24M | -4.83M | -7.78M | -10.04M | -12.85M | -25.92M | Operating Cash Flow |
| -5.54M | -4.39M | -6.29M | -9.05M | -10.45M | -14.24M | Investing Cash Flow |
| 317.00K | 2.29M | -1.49M | -982.00K | -2.40M | -14.14M | Financing Cash Flow |
| 3.49M | -1.44M | 5.55M | 9.89M | 9.18M | 23.77M |
Althea Group Holdings Ltd. Technical Analysis
Althea Group Holdings Ltd. Peers Comparison
Althea Group Holdings Ltd. Corporate Events
Althea Group Holdings Ltd has executed a definitive Asset Sale Agreement to sell certain assets of its subsidiary, Althea Company Pty Ltd, to Tasmanian Botanics Pty Ltd. This strategic move allows AGH to focus entirely on its North American THC-infused beverage operations under the Peak Processing Solutions brand, marking a significant shift in the company’s operational focus. The transaction, valued at $1.0 million with additional profit-sharing terms, will help strengthen AGH’s balance sheet through targeted debt repayment, without impacting its board or executive management.
Althea Group Holdings Limited announced a change in its head office telephone number to +61 3 7044 2936. This update, made in accordance with ASX Listing Rule 3.14, does not affect any other contact details. The change is a minor operational update and is unlikely to have significant implications for stakeholders or the company’s market positioning.
Althea Group Holdings Ltd. has announced a strategic shift by disposing of its pharmaceutical assets to concentrate on the high-growth potential of THC beverages. This move aligns with the company’s focus on expanding its market presence in the U.S. and leveraging its Canadian subsidiary, Peak, which is noted for its scalable business model and high barriers to entry. The strategic realignment is expected to enhance Althea’s industry positioning and provide significant opportunities for growth, impacting stakeholders positively by focusing on a promising segment of the cannabis market.
Althea Group Holdings Limited is set to host a live webinar to discuss its strategic decision to divest its pharmaceutical assets and focus on the global THC-infused beverage market. This move aims to capitalize on the high demand in this segment, particularly in North America, positioning AGH as a leader in this space.
Althea Group Holdings Ltd has appointed Brian Mbesha as its new Chief Financial Officer, effective June 9, 2025. Mr. Mbesha, with over two decades of experience in senior finance roles across North America, will be based at the company’s North American headquarters in Windsor, Ontario. His extensive expertise in financial systems optimization, cost control, and operational efficiency is expected to significantly contribute to AGH’s growth and transformation efforts. The appointment is anticipated to enhance the company’s strategic and operational capabilities as it continues to scale its business in the competitive THC beverage market.
Althea Group Holdings Ltd has announced the withdrawal of its FY25 financial guidance following the sale of its pharmaceutical assets to Tasmanian Botanics Pty Ltd. This strategic divestment allows the company to concentrate its resources on the high-growth North American THC-infused beverage market, where its subsidiaries, Peak Canada and Peak USA, are poised to lead. The move signifies a pivotal shift in AGH’s business strategy, aligning its operations with its evolving focus on the THC beverage sector.
Althea Group Holdings Ltd. has announced the sale of its pharmaceutical assets to Tasmanian Botanics Pty Ltd for $1 million, along with a revenue-sharing arrangement on residual inventory sales. This strategic divestment allows AGH to concentrate on the booming THC-infused beverage market in North America, leveraging its expertise and proprietary technology to capitalize on growing consumer demand. The transaction aligns with AGH’s vision to enhance shareholder value by focusing on high-growth, lower-risk product categories, and ensures continuity of care for Althea’s existing patients and prescribers.
Althea Group Holdings Ltd. has announced a change in the interests of a substantial holder, which impacts the company’s shareholding structure. This change could affect the company’s operations and its positioning in the market, as it may influence stakeholder decisions and company strategy moving forward.
Althea Group Holdings Ltd. announced a change in the director’s interest, with Director Matt Adams acquiring 1,000,000 Ordinary Class Shares through participation in a placement. This acquisition was made following shareholder approval at the company’s General Meeting, indicating a strategic move to strengthen the director’s stake and potentially align management interests with shareholder value. The transaction, valued at $0.02 per share, reflects the company’s ongoing efforts to enhance its capital structure and market positioning.
Althea Group Holdings Ltd. announced a change in the director’s interest, specifically for Director Vaughan Webber, who increased his indirect interest in the company by acquiring an additional 1,000,000 Ordinary Class Shares. This acquisition was made through participation in a placement after receiving shareholder approval at the company’s General Meeting. The change in shareholding reflects a strategic move by the director to increase his stake in the company, potentially indicating confidence in the company’s future prospects and aligning his interests with those of other shareholders.
Althea Group Holdings Ltd has announced a change in the director’s interest, with Director Joshua Fegan acquiring additional securities. The acquisition includes 4,000,000 Ordinary Class Shares and 2,601,564 Performance Rights, following shareholder approval at the company’s General Meeting. This move is part of the company’s strategy to align director interests with company performance, potentially impacting its market positioning and stakeholder confidence.
Althea Group Holdings reported significant financial activities for the quarter ending March 31, 2025, with $5.02 million in customer receipts and strategic investments in inventory pre-purchasing to support future growth. Peak Canada achieved $4.2 million in customer receipts and improved gross margins, while Peak USA commenced commercial operations with strong early demand. Despite a decline in the pharmaceutical cannabis segment, the company is conducting a strategic review to explore profitability restoration. These developments position AGH for potential revenue and profitability growth in the upcoming fiscal periods.
Althea Group Holdings Ltd. announced the application for quotation of 100 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and signifies the company’s ongoing efforts to strengthen its market presence and enhance shareholder value.
Althea Group Holdings Ltd. has announced the issuance of 25 million unquoted equity securities in the form of options to subscribe for ordinary class shares, with an exercise price of $0.03 and an expiration date of April 28, 2027. This move is part of a previously announced transaction, indicating strategic financial maneuvers to potentially enhance capital structure and shareholder value.
Althea Group Holdings Ltd. has announced the issuance of 25 million unquoted options to subscribe for ordinary class shares, with an exercise price of $0.04 and an expiration date of February 28, 2027. This move is part of a previously announced transaction and is expected to enhance the company’s financial flexibility and strategic positioning in the medicinal cannabis market.
Althea Group Holdings Ltd. announced the issuance of unquoted equity securities, specifically options expiring in January 2028. This move is part of a previously announced transaction, indicating strategic financial maneuvers to potentially enhance the company’s capital structure and market positioning.
Althea Group Holdings Ltd. has announced the quotation of 4,574,824 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of April 29, 2025. This move is part of previously announced transactions and is expected to enhance the company’s liquidity and market presence, potentially benefiting shareholders and strengthening its position in the medicinal cannabis sector.
Althea Group Holdings Ltd. announced the quotation of 274,750,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of April 29, 2025. This move is part of previously announced transactions, potentially enhancing the company’s market presence and liquidity, which could have positive implications for stakeholders by increasing the company’s capital base and supporting its growth initiatives.
Althea Group Holdings Ltd. has announced the issuance of 10,163,770 ordinary fully paid securities to be quoted on the ASX as of April 29, 2025. This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding and retaining talent, which may enhance its operational capabilities and market positioning.
Althea Group Holdings Ltd. announced a proposed issue of securities, including options and ordinary shares, to be listed on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to raise capital, potentially enhancing its financial position and market presence in the medicinal cannabis sector.
Althea Group Holdings Limited has announced a Cleansing Offer of up to 100 shares at A$0.10 each, closing on April 29, 2025. The primary purpose of this offer is to remove trading restrictions on the sale of shares to be issued by the company in April 2025, in accordance with section 708A(11) of the Corporations Act.
Althea Group Holdings Ltd announced that all resolutions proposed at their General Meeting were passed by poll. The successful resolutions indicate strong shareholder support for the company’s strategic initiatives, which could positively impact its operations and market positioning in the global cannabis industry.
Althea Group Holdings Ltd. has announced a significant change in its substantial shareholder structure, with a notable increase in shareholding by an unnamed entity. This change is expected to impact the company’s market positioning and could have implications for its strategic direction and stakeholder interests.
Althea Group Holdings Ltd has announced a change in its registered office and principal place of business to Level 19, 180 Lonsdale Street, Melbourne, Victoria 3000, effective immediately. This change is part of the company’s ongoing operational adjustments and does not affect its contact number. The announcement reflects the company’s commitment to maintaining its operational efficiency and presence in key markets.
Althea Group Holdings Ltd. announced a change in the director’s interest, with Alan Boyd transferring 113,718 ordinary shares off-market to closely related entities. This transfer, which reduces Boyd’s direct shareholding to 170,000 shares, is valued at approximately $0.024 per share based on the closing price on March 11, 2025. The off-market transfer indicates a strategic internal reallocation of shares, potentially impacting the company’s governance structure and shareholder dynamics.